About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

ZERIA PHARMACEUTICAL CO.,LTD.(4559) Summary

4559
TSE Prime
ZERIA PHARMACEUTICAL CO.,LTD.
2,220
JPY
-49
(-2.16%)
Apr 4, 10:10 am JST
15.19
USD
Apr 3, 9:13 pm EDT
Result
PTS
outside of trading hours
2,224.1
Apr 4, 10:06 am JST
Summary Chart Historical News Financial Result
PER
10.8
PBR
1.15
Yield
2.07%
Margin Trading Ratio
3.59
Stock Price
Apr 4, 2025
Opening Apr 4, 9:00 am
2,279 JPY 15.58 USD
Previous Close Apr 3
2,269 JPY 15.41 USD
High Apr 4, 9:00 am
2,279 JPY 15.58 USD
Low Apr 4, 10:10 am
2,220 JPY 15.17 USD
Volume
20,400
Trading Value
0.05B JPY 0.32M USD
VWAP
2249.78 JPY 15.37 USD
Minimum Trading Value
222,000 JPY 1,519 USD
Market Cap
0.12T JPY 0.81B USD
Number of Trades
86
Liquidity & Number of Trades
As of Apr 4, 2025
Liquidity
Mid
1-Year Average
269
1-Year High May 10, 2024
1,031
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 28, 2025 12,700 14,400 1.13
Mar 21, 2025 110,500 24,000 0.22
Mar 14, 2025 62,900 25,600 0.41
Mar 7, 2025 32,700 34,800 1.06
Feb 28, 2025 11,200 50,800 4.54
Company Profile
ZERIA PHARMACEUTICAL CO.,LTD. is a mid-tier pharmaceutical company focusing on gastrointestinal products. It also develops over-the-counter drugs such as the nutritional supplement "Hepalyse" and is expanding overseas.
Sector
Pharmaceuticals
ZERIA PHARMACEUTICAL CO.,LTD. operates with prescription pharmaceuticals as its core business, complemented by its consumer healthcare business as a dual revenue stream. In the prescription pharmaceuticals sector, the company manufactures and sells its own products domestically while pursuing international expansion through overseas subsidiaries. The consumer healthcare business encompasses a wide range of products, primarily OTC drugs, as well as health foods and cosmetics. The group consists of 22 subsidiaries and one affiliated company, through which it engages in the sale of health foods and cosmetics, and the manufacture and sale of pharmaceutical raw materials. Additionally, subsidiaries are involved in insurance agency services, real estate, procurement and sales of promotional materials, and various maintenance services. By collaborating with domestic and international subsidiaries and affiliates, ZERIA PHARMACEUTICAL CO.,LTD. has established a global business foundation.